The venture capital arm of GlaxoSmithKline, SR One, has co-led a $33 million venture round for the UK's Syntaxin--a developer focused on cell secretion. The Series B was also co-led by Life Science Partners. Syntaxin's technology is being used to develop proteins that can prevent a cell from secreting hormones or the signaling molecules the play a key role in disease.
"Syntaxin's discovery platform provides a unique approach to the development of a new class of biopharmaceutical products with potential application across a broad range of indications," said Deborah Harland, general partner at SR One.
- see this release for more